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Transurethral resection of the prostate (TURP) is the most common surgical procedure for
relieving symptoms of benign prostatic hyperplasia. Here, we report our experience of current
indications for TURP and their associated outcomes at Kaohsiung Medical University
Hospital (KMUH). A total of 111 patients who underwent TURP at KMUH between May
2000 and December 2001 were included in this retrospective review. For each patient, the
surgical indication was categorized into acute urinary retention, chronic complications
(including renal impairment, recurrent urinary infection, bladder stone/diverticulum, post-
void residue, and recurrent hematuria), and symptomatic prostatism. Thirty-five patients
(31%) had acute urinary retention, 28 (27%) had chronic complications, and 48 (42%) had
symptomatic prostatism. Most patients chose TURP only when medical treatment had failed
to relieve symptoms, no matter what category they belonged to. Patients with acute urinary
retention and chronic complications had larger prostates (p = 0.002) and more tissue resected
(p = 0.05) than those with symptomatic prostatism. Patients with acute urinary retention
seemed to be at greater risk of postoperative complications such as recurrent urinary retention
and urinary tract infection. We suggest that urodynamic study may be necessary to rule
out concomitant bladder dysfunction before surgery and that adequate prophylactic
antibiotic treatment be used to decrease the risk of urinary tract infection during or after
TURP, especially when pyuria is noted preoperatively in patients with acute urinary
retention.
Key Words: transurethral resection, prostate, benign prostatic hyperplasia
(Kaohsiung J Med Sci 2003;19:49–54)
Received: October 28, 2002 Accepted: February 18, 2003
Address correspondence and reprint requests to: Dr. Yii-Her
Chou, Department of Urology, Kaohsiung Medical University,
100 Shih-Chuan 1st Road, Kaohsiung City 807, Taiwan.
E-mail: yihech@kmu.edu.tw
Benign prostatic hyperplasia (BPH) has a high preva-
lence in the male population that increases with age [1,
2]. It often produces chronic and progressive lower
urinary symptoms or chronic complications, leading
many men to seek treatment [2, 3]. Transurethral re-
section of the prostate (TURP) has been the most
common surgical procedure for relieving symptoms
of BPH [4]. It offers a more favorable 5-year impact on
symptoms and BPH complications than watchful
waiting, without a higher risk of incontinence or erec-
tile dysfunction [5]. Since the introduction of medical
therapy and minimally invasive treatments such as
laser and microwave therapy, there has been a dra-
matic decrease in the number of TURPs performed for
symptomatic BPH in the last decade [2, 4]. We report
our experience of TURP for BPH to evaluate current
indications and associated outcomes.
MATERIALS AND METHODS
A retrospective review was performed in all patients
who underwent TURP at Kaohsiung Medical
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University Hospital between May 2000 and December
2001. If prostate cancer was diagnosed preoperatively,
the patient was excluded. All patients were categorized
according to their main indication for TURP: acute
urinary retention,  chronic complications,  or
symptomatic prostatism. Patients with acute urinary
retention were defined as those who had had a Foley
catheter inserted to relieve urinary retention in the 1
m o n t h  b e f o r e  u n d e r g o i n g  T U R P .  C h r o n i c
complications included renal function impairment,
recurrent  urinary infect ion,  bladder  s tone/
diverticulum, post-void residue (> 100 mL), and re-
current hematuria. Patients with none of these prob-
lems who underwent TURP for lower urinary tract
symptoms were categorized as having symptomatic
prostatism.
The results of preoperative investigations, clinical
management, and postoperative conditions were
evaluated. Preoperative investigations included age,
previous medical history of BPH, comorbid diseases,
laboratory test data, and imaging studies. Clinical
management focused on the type of anesthesia,
operative time, the weight of prostatic tissue resected
in TURP, histology, need for blood transfusion, and
use of prophylactic antibiotics. Postoperative
conditions were evaluated on the basis of the number
of postoperative days spent in hospital  and
postoperative complications within 3 months.
Postoperative complications were defined as those
requiring a prolonged hospital stay, an emergency
room visit, repeated surgery, or readmission and
placement of an indwelling Foley catheter due to
urinary retention.
Results are expressed as mean ± standard deviation,
unless otherwise indicated. Statistical differences
between groups were compared using the chi-square
test and ANOVA procedure. A p-value of less than
0.05 was considered statistically significant.
RESULTS
Between May 2000 and December 2001, 115 patients
underwent TURP at Kaohsiung Medical University
Hospital. Four patients were excluded due to previous
diagnosis of prostate cancer, so 111 patients were
included in the study. Of these, 35 (31%) had acute
urinary retention, 28 (27%) had chronic complications,
and 48 (42%) had symptomatic prostatism. Among
patients with chronic complications, recurrent
hematuria was most common (12%; Table 1).
The characteristics of the different groups are
presented in Tables 2 and 3. Mean prostate size
measured by transrectal ultrasound (p = 0.002) and
mean weight of resected prostate during TURP (p =
0.0496) were greater in patients with acute urinary
retention and chronic complications than those with
symptomatic prostatism. Symptomatic prostatism
patients underwent TURP at a younger age (mean, 67
± 7 years) than other patients (p = 0.013). No statistically
significant difference was found among the three
groups in prostate specific antigen (PSA) level,
duration of previous medication, surgical time, and
hospital stay after TURP.
Although no significant difference was noted in
respect to comorbid diseases among the three groups,
there seemed to be a higher prevalence of diabetes
mellitus (17.1%) and cerebrovascular accidents
(14.3%) among patients with acute urinary retention.
In addition, pyuria before TURP was more common
among patients with acute urinary retention than
among other patients (42.9%, p = 0.001). Preoperative
anemia was more common in patients with chronic
complications than in other patients (hemoglobin < 12
mg/dL; 25.0%, p = 0.001), as was the need for blood
transfusion during or after TURP (10.7%, p = 0.01).
There was no obvious statistical difference in the
complication rate in the three groups of patients within
3 months after TURP (Table 4), but patients with acute
urinary retention seemed to have a higher risk of
complications such as urinary tract infection (11.4%),
acute urinary retention (17.1%), hematuria (8.6%), and
readmission (14.3%) and re-operation (5.7%) for
Table 1. Indications for transurethral resection of the
prostate
Surgical indication n %
Acute urinary retention 35 31
Symptomatic prostatism 48 42
Chronic complications
Bladder stone/diverticulum 5 5
Post-void residue 4 4
Recurrent hematuria 13 12
Recurrent UTI 4 4
Renal function impairment 2 2
Total 111
UTI = urinary tract infection.
Current indications for transurethral resection of the prostate
51Kaohsiung J Med Sci February 2003 • Vol 19 • No 2
complications. Only one patient (0.9%) suffered from
TUR syndrome in this study.
Three patients needed secondary operations for
management of complications after TURP. Two
originally had acute urinary retention and underwent
endoscopy to remove blood clots due to persistent
hematuria. The other patient originally had chronic
complications and underwent suprapubic cystostomy
due to persistent urinary retention after TURP.
DISCUSSION
BPH is a common condition among older men, resulting
in chronic lower urinary tract symptoms that are
bothersome, impaired physiologic and functional well-
being, and interference with activities of daily living
[6, 7]. The prevalence of BPH increases with age. A
community-based survey involving more than 2,000
men aged 40–79 years living in Olmsted County, MN,
Table 3. Clinical management
AUR (n = 35) SP (n = 48) CC (n = 28) p value
Prostate size (g)* 56 ± 22 42 ± 17 56 ± 18 0.002
Weight of resected prostate (g)* 12 ± 7 10 ± 8 15 ± 10 0.0496
General anesthesia 1 (2.9%) 0 (0%) 1 (3.6%) 0.45
Blood transfusion 0 (0%) 0 (0%) 3 (10.7%) 0.01
Surgical time (min)* 83 ± 32 69 ± 31 82 ± 34 0.119
Hospital stay (d)* 4.5 ± 1.9 4.4 ± 1.0 4.8 ± 2.0 0.597
*Mean ± standard deviation. AUR = acute urinary retention; SP = symptomatic prostatism; CC = chronic complications. †ANOVA; ‡chi-square test
Table 2. Results of preoperative investigations
AUR (n = 35) SP (n = 48) CC (n = 28) p value
Age (yr)* 70 ± 8 67 ± 7 72 ± 7 †0.013
Duration of medication (mo)* 10 ± 18 19 ± 21 24 ± 30 †0.058
DM 6 (17.1%) 6 (12.5%) 2 (7.1%) ‡0.494
H/T 16 (45.7%) 17 (35.4%) 10 (35.7%) ‡0.592
CVD 3 (8.6%) 7 (14.6%) 2 (7.1%) ‡0.527
CVA 5 (14.3%) 3 (6.3%) 2 (7.1%) ‡0.416
Hb < 12 mg/dL 8 (22.9%) 0 (0%) 7 (25.0%) ‡0.001
Cr > 1.5 mg/dL 5 (14.3%) 6 (12.5%) 6 (21.4%) ‡0.569
PSA (ng/mL)* 9.7 ± 8.4 6.1 ± 8.6 7.6 ± 5.9 †0.175
Pyuria 15 (42.9%) 4 (8.3%) 6 (21.4%) ‡0.001
Abnormal ECG 10 (28.6%) 15 (31.3%) 14 (50%) ‡0.158
*Mean ± standard deviation. AUR = acute urinary retention; SP = symptomatic prostatism; CC = chronic complications; DM = diabetes mellitus;
H/T = hypertension; CVD = cardiovascular disease; CVA = cerebrovascular accident; Hb = hemoglobin; Cr = creatinine; PSA = prostate specific
antigen; ECG = electrocardiogram. †ANOVA; ‡chi-square test.
Table 4. Complications 3 months after transurethral resection of the prostate (TURP)
AUR (n = 35) SP (n = 48) CC (n = 28) Total (n = 111) p value*
UTI 4 (11.4%) 2 (4.2%) 2 (7.1%) 8 (7.2%) 0.45
Hematuria 3 (8.6%) 2 (4.2%) 0 (0%) 5 (4.5%) 0.262
AUR 6 (17.1%) 3 (6.3%) 4 (14.3%) 13 (11.7%) 0.278
Re-operation 2 (5.7%) 0 (0%) 1 (3.6%) 3 (2.7%) 0.27
Readmission 5 (14.3%) 4 (8.3%) 2 (7.1%) 11 (9.9%) 0.57
AUR = acute urinary retention; SP = symptomatic prostatism; CC = chronic complications; UTI = urinary tract infection. *Chi square test.
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USA, identified the number of men that meet the
Agency for Health Care Policy and Research (AHCPR)
criterion of having moderate to severe lower urinary
tract symptoms, i.e. an AUA score of more than 7. It
appears that 26% of men aged 40–49 years have mod-
erate to severe lower urinary tract symptoms. This
increases to 46% of men aged 70–79. Somewhat more
than half of these men seem to be more than a little
bothered by their urinary symptoms (13% of men aged
40–49 and 30% of men aged 70–79 years) [1, 8].
The main reasons for patients to seek treatment for
BPH were subjective symptoms,  bothersome
symptoms, and a negative impact on quality of life.
About a decade ago, men with symptomatic BPH
could only choose from two options: watchful waiting
and surgery. Now, several methods are available to
relieve symptoms of BPH, including medical therapies
such as α1-adrenoceptor antagonists and finasteride,
surgery such as open prostatectomy and TURP, and
several minimally invasive treatments such as laser
therapy and microwave therapy [2, 3]. TURP is still
thought to be the “gold standard“ surgical procedure
[9, 10] and to be more effective in managing lower
urinary tract symptoms of BPH than laser therapy and
conservative treatment [11–14]. However, the number
of TURPs dropped significantly during the early 1990s
in the USA (about 50% from 1984–1990 to 1991–1997).
This is probably due to the availability of medical
therapy for the treatment of symptomatic BPH [4, 8].
What is the indication for TURP now? It is generally
reserved for patients who do not have a sufficient
response to medical therapy and those with absolute
indications for intervention, such as complete
retention, recurrent infection or hematuria, renal
insufficiency, and bladder stones [9, 15]. Borth et al
found a 60% decrease in the total number of TURPs
performed in their hospital for symptomatic BPH in
1998 compared with 1988, despite a 16% increase in
men at risk of BPH-related events [2]. Previous medical
management had failed in 36% of the men who required
TURP in 1998 and a significantly higher percentage of
patients presented with acute urinary retention (55%)
and upper tract obstructive uropathy (12.5%) in 1998
compared with 1988 (23% and 1.3%, respectively). In
our study, most patients had received medical therapy
for BPH symptoms before they underwent TURP. The
average duration of medication for BPH was 6 months.
Of the patients who underwent TURP, the indication
was BPH complications in 58% (acute urinary retention,
31%; chronic complications, 27%). These patients had
larger prostates (p = 0.002) and more tissue resected
(p = 0.0496) compared with patients who had sympto-
matic prostatism.
Patients with acute urinary retention had the
shortest average duration of medication for BPH before
TURP. They also had more postoperative complications
(urinary tract infection, 11%; hematuria, 8.6%; urinary
retention, 17.1%), a higher readmission rate (14.3%),
and the highest incidence of pyuria before TURP
(42.9%, p = 0.002). The significant proportion of pa-
tients with pyuria may pose a higher risk of urinary
tract infection during and after TURP. These patients
also seemed to be at greater risk of urinary retention
after TURP. The possible causes of urinary retention
included blood clot obstruction, acute infection, and
poor detrusor contractility.  Because a higher
prevalence of diabetes and cerebrovascular accident
were also noted in patients with acute urinary retention
compared with other patients, we suggest that
urodynamic study in the preoperative evaluation of
patients with acute urinary retention may be needed
to rule out the possibility of concomitant bladder
dysfunction.
Patients with symptomatic prostatism seemed to
be more healthy in several aspects (no pyuria, normal
hemoglobin level, and normal renal function)
compared with other patients. They also had a shorter
hospital stay and few complications after TURP.
In this study, three patients who needed blood
transfusions all had chronic complications. The
possible causes may be the higher percentage of
recurrent hematuria (44%) and the significant incidence
of preoperative anemia (25%) in these patients.
What is the appropriate amount of tissue to remove
during TURP compared with the prostatic volume
measured by ultrasound preoperatively? There is no
definite conclusion according to previous studies [16,
17]. The recommended TURP technique completely
removes all adenomatous tissue. However, the
perioperative morbidity of TURP in terms of blood
loss and fluid inflow is related to the size of the
prostate. Hence, limited resection techniques (minimal
TURP, channel TURP) have been introduced to reduce
the morbidity of transurethral resection, and have
gained some popularity [16, 18]. Other possible factors
influencing the amount of tissue resected during TURP
may include the health of the patient, the surgeon’s
preference and experience, and the welfare health
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system. Further studies may be needed to evaluate the
correlation among these factors.
In conclusion, most patients will choose medical
therapy as first-line treatment for BPH. TURP should
be reserved for patients who are refractory to medical
therapy and/or have complications of BPH. Patients
who undergo TURP for acute urinary retention seem
to be at greater risk of postoperative complications
such as recurrent urinary retention and urinary tract
infection. We suggest that urodynamic study may be
necessary to rule out concomitant bladder dysfunction
before surgery and that adequate prophylactic
antibiotic treatment should be used to decrease the
risk of urinary tract infection during or after TURP,
especially when pyuria is noted preoperatively.
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